Unfit patients even have the alternative of venetoclax additionally obinutuzumab (VO) as frontline therapy. This relies with a phase III demo that in comparison VO with ClbO in elderly/unfit patients.113 VO was superior with regards to response charge and progression-totally free survival, and experienced a similar safety profile. In this https://kirkq753sbi1.qodsblog.com/profile